Every Form 4 that NeuroOne Medical Technologies Corporation (NMTC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NMTC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NMTC filings page.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Chief Business Officer David J. Wambeke reported two insider transactions. On August 27, 2026, he purchased 33,333 shares of common stock at a weighted average price of about $2.01 per share, with individual trade prices between $2.00 and $2.017, bringing his direct common share holdings to 199,999 shares. On August 28, 2026, he received a grant of 35,000 stock options with an exercise price of $1.77 per share, expiring on August 27, 2036; 25% of these options will vest on August 28, 2027 and the remaining 75% will vest in 12 equal quarterly installments. No Rule 10b5-1 trading plan is reported for these transactions.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) reported that Chief Administrative Officer Emily J. Johns received a grant of stock options. The award covers 12,500 options to purchase common shares at an exercise price of $1.77 per share, expiring on August 27, 2036. Following this grant, she holds 12,500 options. According to the vesting terms, 25% of the options will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments thereafter.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) reported that Chief Financial Officer Christopher Volker received a grant of options to purchase 35,000 shares of common stock. The options have an exercise price of $1.77 per share and expire on August 27, 2036. According to the vesting terms, 25% of the options will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments thereafter. Following this award, Volker holds 35,000 option shares directly from this grant.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) reported that officer Mark Christianson received a grant of 12,500 options to purchase common stock. The options have an exercise price of $1.77 per share and expire on August 27, 2036. According to the vesting terms, 25% of the options vest on August 28, 2027, with the remaining 75% vesting in 12 equal quarterly installments thereafter. Following this award, Christianson directly holds 12,500 derivative securities related to NMTC common stock.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) reported that Chief Technology Officer Steve Mertens received a grant of an option to purchase 15,000 shares of common stock. The option has an exercise price of $1.77 per share and expires on August 27, 2036. According to the vesting terms, 25% of the option will vest on August 28, 2027, with the remaining 75% vesting in 12 equal quarterly installments thereafter. Following this grant, Mertens holds 15,000 derivative securities directly.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) reported that CEO and President David A. Rosa received a grant of stock options covering 68,000 shares of common stock. The options have an exercise price of $1.77 per share, expire on August 27, 2036, and are held directly. According to the vesting terms, 25% will vest on August 28, 2027, with the remaining 75% vesting in 12 equal quarterly installments. Following this award, he holds options to purchase 68,000 shares from this grant.
NEUROONE MEDICAL TECHNOLOGIES Corp Market Development Director Mark Christianson reported an open-market sale of 10,000 shares of Common Stock at an average price of $3.1773 per share. After this transaction, he directly holds 20,692 shares, indicating he retained a substantial remaining equity position in the company.
NEUROONE MEDICAL TECHNOLOGIES Corp director Jason Richard Mills reported equity compensation awards. He received options to purchase 26,036 shares of common stock at an exercise price of $0.795 per share, expiring on April 2, 2036, vesting in 12 equal monthly installments.
He also received a grant of 41,929 restricted stock units that vest in 12 equal monthly installments over one year, with vesting at the end of each month. Following the stock grant, he holds 49,687 shares of common stock directly.
NEUROONE MEDICAL TECHNOLOGIES Corp director Jeffrey S. Mathiesen received new equity compensation. On April 3, 2026, he was granted options to purchase 26,036 shares of common stock at an exercise price of $0.795 per share, expiring on April 2, 2036. These options vest in 12 equal monthly installments over one year.
On the same date, he also received 41,929 restricted stock units, which vest in 12 equal monthly installments over one year at the end of each month. Following these grants, he directly owns 156,343 shares of common stock. Both grants are compensation awards rather than open-market purchases.
NeuroOne Medical Technologies director Paul Buckman received new equity awards as compensation. He was granted an option to purchase 26,036 shares of common stock at an exercise price of $0.795 per share, expiring on April 2, 2036, vesting in 12 equal monthly installments over one year.
He was also granted 41,929 restricted stock units that vest in 12 equal monthly installments over the same one-year period, with vesting at the end of each month. Following these awards, he directly holds 178,733 shares of common stock. These are grants, not open-market purchases.
NeuroOne Medical Technologies board member Edward Andrle reported receiving new equity awards. He was granted an option to purchase 26,036 shares of common stock at an exercise price of $0.795 per share, expiring on April 2, 2036, vesting in 12 equal monthly installments over one year.
He also received 41,929 restricted stock units that vest in 12 equal monthly installments over the same one-year period, with vesting at each month-end. Following the stock grant, Andrle directly holds 133,932 shares of common stock.
NeuroOne Medical Technologies officer Mark Christianson reported recent transactions in the company’s Common Stock. On March 30, he completed an open-market sale of 15,363 shares at $0.74 per share. On March 31, an additional 253 shares were disposed of as a tax-withholding transaction, covering tax obligations rather than representing a market trade.
Following these transactions, Christianson holds 198,667 shares of NeuroOne Common Stock directly, according to the filing. The activity reflects a net reduction in his position, primarily driven by the open-market sale, with the smaller tax-withholding disposition tied to equity-related compensation.
NEUROONE MEDICAL TECHNOLOGIES Corp Chief Technology Officer Steve Mertens reported a small share disposition related to taxes, not an open-market trade. On this Form 4, 906 shares of common stock were withheld at $0.777 per share to satisfy a tax obligation. Following this tax-withholding disposition, Mertens directly holds 152,141 shares of common stock.
NEUROONE MEDICAL TECHNOLOGIES Corp director and CEO David A. Rosa reported a tax-related share disposition. On the reported date, 2,458 shares of Common Stock were delivered at $0.777 per share as a tax-withholding disposition to cover exercise price or tax liabilities. After this non-market transaction, he directly owned 1,080,132 shares of Common Stock.
NEUROONE MEDICAL TECHNOLOGIES Corp executive Mark Christianson, Business Development Director, reported small open-market sales of company common stock. He sold 817 shares on March 12, 2026 and 100 shares on March 13, 2026, both at $0.80 per share. After these transactions, he directly holds 214,283 shares of NeuroOne common stock.
NEUROONE MEDICAL TECHNOLOGIES Corp officer Mark Christianson reported open-market sales of a total of 13,720 shares of common stock at weighted average prices around $0.80 per share on March 10–11, 2026. After these transactions, he directly holds 215,200 shares of common stock.
NEUROONE MEDICAL TECHNOLOGIES Corp’s Chief Business Officer, David J. Wambeke, reported acquiring both stock options and common shares. On March 1, 2026, he received an option to purchase 500,000 shares of common stock at an exercise price of $0.00 per share. According to the terms, 25% of this option will vest on March 1, 2027, with the remaining 75% vesting in 12 equal quarterly installments starting March 31, 2027. On the same date, he also made an open-market purchase of 1,000,000 shares of common stock at a price of $0.6704 per share, bringing his directly owned common stock position to 1,000,000 shares.
NEUROONE MEDICAL TECHNOLOGIES Corp Chief Technology Officer Steve Mertens reported a Form 4 transaction involving company common stock. On this date, 7,376 shares were disposed of at a price of $0.68 per share as a tax-withholding disposition rather than an open-market sale. Following this transaction, Mertens directly owned 153,047 shares of NEUROONE MEDICAL TECHNOLOGIES Corp common stock.
NeuroOne Medical Technologies Corp officer Mark Christianson reported a tax-related share disposition. On February 18, 2026, he disposed of 1,812 shares of common stock at $0.68 per share to cover tax withholding. Following this transaction, he directly owns 228,920 common shares of the company.
NEUROONE MEDICAL TECHNOLOGIES Corp CEO and President David A. Rosa reported a Form 4 transaction involving company common stock. On February 18, 2026, he disposed of 71,325 shares at $0.68 per share in a tax-withholding disposition related to equity compensation, not an open-market sale. After this transaction, he directly owned 1,082,590 common shares.